aprepitant

Brand: Emend

Prototype Drug
Drug Class: antiemetic
Drug Family: antiemetic
Subclass: neurokinin-1 (NK1) receptor antagonist
Organ Systems: gastrointestinal

Mechanism of Action

NK1 receptor antagonist blocking substance P action centrally and peripherally; most effective for delayed CINV (24-120h post-chemo); used in triple antiemetic regimens.

neurokinin-1 (substance P) receptor

Indications

  • highly emetogenic chemotherapy CINV (prevention)
  • post-operative nausea/vomiting (prevention)

Contraindications

  • concurrent pimozide
  • concurrent cisapride

Adverse Effects

Common

  • fatigue
  • hiccups
  • diarrhea
  • constipation

Serious

  • severe hypersensitivity

Pharmacokinetics (ADME)

Absorption ~60-65% oral
Distribution large Vd
Metabolism extensive hepatic CYP3A4 and CYP1A2
Excretion renal negligible, fecal
Half-life 9-13 hours
Onset 3-5 hours
Peak 4 hours
Duration delayed CINV ~120h
Protein Binding 97%
Vd 66-99 L

Drug Interactions

Drug / Agent Mechanism Severity
strong CYP3A4 inhibitors increase aprepitant levels major
CYP3A4 substrates (warfarin, oral contraceptives) aprepitant inhibits CYP3A4 — increases their levels major
oral contraceptives CYP3A4 induction 2 weeks after last dose — reduces OC efficacy; use backup contraception major

Nursing Considerations

  1. Triple antiemetic regimen: aprepitant + ondansetron + dexamethasone
  2. Use backup contraception for 1 month after last dose (CYP3A4 induction reduces OC efficacy)
  3. Monitor INR if on warfarin
  4. Take 1 hour before chemotherapy on day 1; continue day 2 and 3

Clinical Pearls

  • Prevents delayed CINV (peaks 48-72h post-chemo) — ondansetron alone insufficient
  • CYP3A4 net inhibitor then inducer over time: immediate inhibition, then induction — reduces OC efficacy with prolonged use

Safety Profile

Pregnancy avoid
Lactation avoid
Renal Adjustment Not required
Hepatic Adjustment Required
TDM Not required

Concordance Terms

Cross-referenced clinical concepts — click any term to see all content where it appears.